NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 12-22. PMID: 31910384, DOI: 10.6004/jnccn.2020.0002.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiosimilar PharmaceuticalsChemotherapy-Induced Febrile NeutropeniaDrug ApprovalDrug CostsEducation, Medical, ContinuingHematopoietic Cell Growth FactorsHumansMedical OncologyNeoplasmsOncologistsOrganizations, NonprofitPractice Guidelines as TopicRisk FactorsUnited StatesUnited States Food and Drug AdministrationConceptsFebrile neutropeniaNCCN guidelinesHematopoietic growth factorsGrowth factorManagement of FNTreatment of FNSelect patientsSupportive careNonmyeloid malignanciesCancer treatmentAppropriate evaluationAppropriate usePatientsRisk determinationTreatmentImportant updatesGuidelinesNeutropeniaProphylaxisMalignancyCliniciansFactorsCarePrevention